Related Experiment Videos
Enteryx.
Hubert Louis1, Jean Closset, Jacques Devière
1Department of Gastroenterology and Hepatopancreatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. hlouis@ulb.ac.be
Summary
Enteryx, an endoscopic bulking agent, shows promise for treating gastro-oesophageal reflux disease (GORD) by improving symptoms and reducing medication needs. Further studies are required to confirm its long-term efficacy as a GORD therapy.
Area of Science:
- Gastroenterology
- Medical Devices
- Surgical Innovation
Background:
- Gastro-oesophageal reflux disease (GORD) affects many patients, often managed with medication or surgery.
- Existing treatments for GORD have limitations and potential side effects.
- A minimally invasive endoscopic approach is desired for GORD management.
Purpose of the Study:
- To evaluate the safety and efficacy of Enteryx, an ethylene vinyl alcohol copolymer bulking agent, for GORD treatment.
- To assess the impact of Enteryx implantation on reflux symptoms and medication use.
- To investigate the effect of Enteryx on lower oesophageal sphincter (LOS) function and acid exposure.
Main Methods:
- Prospective, multicentre clinical studies involving endoscopic injection of Enteryx at the lower oesophageal sphincter (LOS).
- Assessment of GORD symptoms, proton pump inhibitor (PPI) usage, and oesophageal acid exposure.
- Evaluation of implant persistence and LOS pressure changes over a 6-month follow-up period.
Main Results:
- Enteryx implantation was a fast, minimally invasive, and safe procedure.
- Significant improvements in GORD symptoms and a reduction in PPI use were observed.
- Objective improvements in oesophageal acid exposure time were noted.
- Preliminary data suggest Enteryx may lengthen the LOS and increase relaxation pressure.
Conclusions:
- Enteryx demonstrates potential as an effective endoscopic treatment for GORD.
- Symptom improvement appears linked to implant persistence.
- Further controlled studies with longer follow-up are necessary to validate Enteryx as a routine GORD therapy.